Works matching DE "SUBTILISIN inhibitors"

Results: 37

Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications.

Published in:

2018

By:

Wasserman, Scott M.;
Sabatine, Marc S.;
Koren, Michael J.;
Giugliano, Robert P.;
Legg, Jason C.;
Emery, Maurice G.;
Doshi, Sameer;
Liu, Thomas;
Somaratne, Ransi;
Gibbs, John P.

Publication type:

journal article

Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables.

Published in:

2018

By:

Filippatos, Theodosios D.;
Kei, Anastazia;
Rizos, Christos V.;
Elisaf, Moses S.

Publication type:

journal article

GAUSS-2, RUTHERFORD-2, LAPLACE-2, DESCARTES, and TESLA Part B: PCSK9 inhibitors gain momentum.

Published in:

Global Cardiology Science & Practice, 2014, v. 2014, n. 4, p. 184, doi. 10.5339/gcsp.2014.49

By:

Hassan, Mohamed;
Yacoub, Magdi

Publication type:

Article

Subtilisin inhibitor like protein ' ppLPI-1' from leaves of pigeonpea ( Cajanus cajan, cv. BSMR 736) exhibits inhibition against Helicoverpa armigera gut proteinases.

Published in:

3 Biotech, 2017, v. 8, n. 1, p. 1, doi. 10.1007/s13205-017-1040-y

By:

Shaikh, Faiyaz;
Gadge, Prafull;
Padul, Manohar;
Kachole, Manvendra

Publication type:

Article

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years.

Published in:

2018

By:

de Carvalho, Luiz Sérgio F.;
Campos, Alessandra M.;
Sposito, Andrei C.

Publication type:

journal article

Efficacy, Safety and Clinical Applicability of PCSK9 Inhibitors.

Published in:

Revista Argentina de Cardiología, 2020, v. 88, n. 2, p. 150, doi. 10.7775/rac.v88.i2.17470

By:

MASSON, WALTER;
GIORGI, MARIANO

Publication type:

Article

Properties and Specific Functional Features of Wheat Grain α-Amylase/Subtilisin Inhibitor.

Published in:

Applied Biochemistry & Microbiology, 2018, v. 54, n. 2, p. 215, doi. 10.1134/S0003683818020059

By:

Kuzovlev, V. A.;
Beskempirova, Zh. D.;
Shansharova, D. A.;
Fursov, O. V.;
Khakimzhanov, A. A.

Publication type:

Article

Subtilisin protease increases digestible energy content but not protein digestibility in sorghum- and wheat-based diets.

Published in:

Animal Production Science, 2015, v. 55, n. 11, p. 1538, doi. 10.1071/ANv55n12Ab049

By:

Cadogan, D. J.;
Dunshea, F. R.

Publication type:

Article

Detection of an Intracellular Protease Inhibitor in Archaea.

Published in:

Current Microbiology, 2003, v. 46, n. 5, p. 0334, doi. 10.1007/s00284-002-3861-z

By:

Giménez, María I.;
Sánchez, Jorge J.;
De Castro, Rosana E.

Publication type:

Article

CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?

Published in:

Diseases, 2018, v. 6, n. 2, p. 45, doi. 10.3390/diseases6020045

By:

Kjellmo, Christian Abendstein;
Hovland, Anders;
Lappegård, Knut Tore

Publication type:

Article

Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.

Published in:

2017

By:

Wójcik, Cezary

Publication type:

journal article

Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9.

Published in:

PLoS ONE, 2017, v. 12, n. 7, p. 1, doi. 10.1371/journal.pone.0180869

By:

Romagnuolo, Rocco;
Scipione, Corey A.;
Marcovina, Santica M.;
Gemin, Matthew;
Seidah, Nabil G.;
Boffa, Michael B.;
Koschinsky, Marlys L.

Publication type:

Article

Medication‐based versus target‐based lipid management.

Published in:

Journal of Diabetes, 2018, v. 10, n. 10, p. 789, doi. 10.1111/1753-0407.12789

By:

Fazio, Sergio;
Shapiro, Michael D.

Publication type:

Article

Lowering LDL‐Cholesterol and CV Benefits: Is There a Limit to How Low LDL‐C Needs to be for Optimal Health Benefits?

Published in:

Clinical Pharmacology & Therapeutics, 2018, v. 104, n. 2, p. 290, doi. 10.1002/cpt.1133

By:

Vani, Anish;
Underberg, James A.

Publication type:

Article

Therapeutic Agents Targeting Cardiometabolic Risk for Preventing and Treating Atherosclerotic Cardiovascular Diseases.

Published in:

Clinical Pharmacology & Therapeutics, 2018, v. 104, n. 2, p. 257, doi. 10.1002/cpt.1110

By:

Arsenault, Benoit J.;
Perrot, Nicolas;
Puri, Rishi

Publication type:

Article

Pcsk9 Knockout Aggravated Experimental Apical Periodontitis via LDLR.

Published in:

Journal of Dental Research, 2022, v. 101, n. 1, p. 83, doi. 10.1177/00220345211015128

By:

Huang, L.;
Wu, H.;
Wu, Y.;
Song, F.;
Zhang, L.;
Li, Z.;
Sun, H.;
Huang, C.

Publication type:

Article

Arabidopsis subtilase SASP is involved in the regulation of ABA signaling and drought tolerance by interacting with OPEN STOMATA 1.

Published in:

Journal of Experimental Botany, 2018, v. 69, n. 18, p. 4403, doi. 10.1093/jxb/ery205

By:

Wang, Qianqian;
Guo, Qianli;
Guo, Yuanyuan;
Yang, Jieshu;
Wang, Min;
Duan, Xiaoke;
Niu, Jiayu;
Liu, Shuai;
Zhang, Jianzhen;
Lu, Yanke

Publication type:

Article

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.

Published in:

2017

By:

Jetty, Vybhav;
Glueck, Charles J.;
Lee, Kevin;
Goldenberg, Naila;
Prince, Marloe;
Kumar, Ashwin;
Goldenberg, Michael;
Anand, Ishan;
Ping Wang;
Wang, Ping

Publication type:

journal article

Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders.

Published in:

2016

By:

Gupta, Sanjiv

Publication type:

journal article

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.

Published in:

2016

By:

Blom, Dirk J.;
Dent, Ricardo;
Castro, Rita C.;
Toth, Peter P.

Publication type:

journal article

PCSK9 Inhibitors and the Choice Between Innovation, Efficiency, and Affordability.

Published in:

2017

By:

Mark, Daniel B.;
Schulman, Kevin A.

Publication type:

Editorial

Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.

Published in:

2017

By:

Kazi, Dhruv S.;
Penko, Joanne;
Coxson, Pamela G.;
Moran, Andrew E.;
Ollendorf, Daniel A.;
Tice, Jeffrey A.;
Bibbins-Domingo, Kirsten

Publication type:

journal article

Thumbs Up for PCSK9 Inhibitors.

Published in:

JAMA: Journal of the American Medical Association, 2015, v. 314, n. 3, p. 217, doi. 10.1001/jama.2015.7582

By:

Voelker, Rebecca

Publication type:

Article

A Proteinaceous Fraction of Wheat Bran May Interfere in the Attachment of Enterotoxigenic <i>E. Coli</i> K88 (F4+) to Porcine Epithelial Cells.

Published in:

PLoS ONE, 2014, v. 9, n. 8, p. 1, doi. 10.1371/journal.pone.0104258

By:

González-Ortiz, Gemma;
Bronsoms, Sílvia;
Quarles Van Ufford, H. C.;
Halkes, S. Bart A.;
Virkola, Ritva;
Liskamp, Rob M. J.;
Beukelman, Cees J.;
Pieters, Roland J.;
Pérez, José Francisco;
Martín-Orúe, Susana María

Publication type:

Article

PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease.

Published in:

Diabetes, Obesity & Metabolism, 2018, v. 20, n. 2, p. 270, doi. 10.1111/dom.13070

By:

Page, Michael M.;
Watts, Gerald F.

Publication type:

Article

Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II.

Published in:

Diabetes, Obesity & Metabolism, 2017, v. 19, n. 7, p. 989, doi. 10.1111/dom.12909

By:

Leiter, Lawrence A.;
Zamorano, José Luis;
Bujas‐Bobanovic, Maja;
Louie, Michael J.;
Lecorps, Guillaume;
Cannon, Christopher P.;
Handelsman, Yehuda

Publication type:

Article

PCSK9 Inhibitors: Lots of Work Done, Lots More to Do.

Published in:

2016

By:

Lauer, Michael S.

Publication type:

journal article

PCSK9 Inhibitor Slashes LDL-C in Statin-Intolerant Patients (GAUSS-2).

Published in:

MD Conference Express, 2014, v. 14, n. 4, p. 17, doi. 10.1177/155989771404007

By:

Kuznar, Wayne

Publication type:

Article

Monoclonal Antibody Reduces LDL-C in Presence of Statin (LAPLACE-2).

Published in:

MD Conference Express, 2014, v. 14, n. 4, p. 15, doi. 10.1177/155989771404005

By:

Kuznar, Wayne

Publication type:

Article

The transglutaminase activating metalloprotease inhibitor from Streptomyces mobaraensis is a glutamine and lysine donor substrate of the intrinsic transglutaminase

Published in:

FEBS Letters, 2008, v. 582, n. 20, p. 3132, doi. 10.1016/j.febslet.2008.07.049

By:

Schmidt, Susan;
Adolf, Frank;
Fuchsbauer, Hans-Lothar

Publication type:

Article

Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes

Published in:

FEBS Letters, 2008, v. 582, n. 6, p. 949, doi. 10.1016/j.febslet.2008.02.038

By:

Langhi, Cédric;
Le May, Cédric;
Kourimate, Sanae;
Caron, Sandrine;
Staels, Bart;
Krempf, Michel;
Costet, Philippe;
Cariou, Bertrand

Publication type:

Article

Bacillus pumilus strains with inactivated genes of extracellular serine proteinases.

Published in:

Microbiology (00262617), 2013, v. 82, n. 1, p. 59, doi. 10.1134/S0026261713010141

By:

Toymentseva, A.;
Akhmetova, A.;
Karimova, M.;
Nyamsuren, C.;
Ponomareva, Yu.;
Shagimardanova, E.;
Rizvanov, A.;
Sharipova, M.

Publication type:

Article

The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Nonfasting Remnant Cholesterol in a Real World Population.

Published in:

Journal of Lipids, 2018, p. 1, doi. 10.1155/2018/9194736

By:

Morise, Anthony P.;
Tennant, Jennifer;
Holmes, Sari D.;
Tacker, Danyel H.

Publication type:

Article

Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial.

Published in:

European Heart Journal, 2021, v. 42, n. 47, p. 4821, doi. 10.1093/eurheartj/ehab604

By:

Oyama, Kazuma;
Giugliano, Robert P;
Tang, Minao;
Bonaca, Marc P;
Saver, Jeffrey L;
Murphy, Sabina A;
Ruzza, Andrea;
Keech, Anthony C;
Sever, Peter S;
Sabatine, Marc S;
Bergmark, Brian A

Publication type:

Article

The European Medicines Agency's approval of proprotein convertase subtilisin/kexin type 9 inhibitors.

Published in:

European Heart Journal, 2021, v. 42, n. 18, p. e2, doi. 10.1093/eurheartj/ehv673

By:

Blind, Eberhard;
Graeff, Pieter A de;
Meurs, Illiana;
Holtkamp, Frank;
Baczynska, Ania;
Janssen, Heidi

Publication type:

Article

Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial.

Published in:

European Heart Journal, 2020, v. 41, n. 42, p. 4114, doi. 10.1093/eurheartj/ehaa498

By:

Tuñón, José;
Steg, Philippe Gabriel;
Bhatt, Deepak L;
Bittner, Vera A;
Díaz, Rafael;
Goodman, Shaun G;
Jukema, J Wouter;
Kim, Yong-Un;
Li, Qian H;
Mueller, Christian;
Parkhomenko, Alexander;
Pordy, Robert;
Sritara, Piyamitr;
Szarek, Michael;
White, Harvey D;
Zeiher, Andreas M;
Schwartz, Gregory G;
Investigators, for the ODYSSEY OUTCOMES

Publication type:

Article

Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study.

Published in:

Lipids in Health & Disease, 2017, v. 16, p. 1, doi. 10.1186/s12944-017-0493-7

By:

Choi, Joshua;
Khan, Amir M.;
Jarmin, Michael;
Goldenberg, Naila;
Glueck, Charles J.;
Ping Wang

Publication type:

Article